164 related articles for article (PubMed ID: 30481158)
1. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre.
Asioli S; Righi A; Iommi M; Baldovini C; Ambrosi F; Guaraldi F; Zoli M; Mazzatenta D; Faustini-Fustini M; Rucci P; Giannini C; Foschini MP
Eur J Endocrinol; 2019 Feb; 180(2):127-134. PubMed ID: 30481158
[TBL] [Abstract][Full Text] [Related]
2. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
4. A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s.
Guaraldi F; Zoli M; Righi A; Gibertoni D; Marino Picciola V; Faustini-Fustini M; Morandi L; Bacci A; Pasquini E; Mazzatenta D; Asioli S
Clin Endocrinol (Oxf); 2020 Jul; 93(1):36-43. PubMed ID: 32306401
[TBL] [Abstract][Full Text] [Related]
5. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
7. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
8. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
9. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
10. Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients.
Lelotte J; Mourin A; Fomekong E; Michotte A; Raftopoulos C; Maiter D
Eur J Endocrinol; 2018 Mar; 178(3):237-246. PubMed ID: 29259039
[TBL] [Abstract][Full Text] [Related]
11. Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.
Astaf'eva LI; Kadashev BA; Shishkina LV; Kalinin PL; Fomichev DV; Kutin MA; Aref'eva IA; Dzeranova LK; Sidneva YG; Klochkova IS; Rotin DL
Zh Vopr Neirokhir Im N N Burdenko; 2016; 80(6):24-35. PubMed ID: 28139570
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
[TBL] [Abstract][Full Text] [Related]
13. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.
Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I
Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875
[TBL] [Abstract][Full Text] [Related]
15. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis.
Chen Y; Cai F; Cao J; Gao F; Lv Y; Tang Y; Zhang A; Yan W; Wang Y; Hu X; Chen S; Dong X; Zhang J; Wu Q
Front Endocrinol (Lausanne); 2021; 12():793337. PubMed ID: 34970226
[TBL] [Abstract][Full Text] [Related]
17. [Trans-septo-sphenoidal operation for pituitary adenoma in 92 patients: results and follow-up endocrine studies].
Gasser RW; Spoendlin H; Finkenstedt G; Pallua AK; Aichner F; Braunsteiner H
Wien Klin Wochenschr; 1993; 105(7):204-7. PubMed ID: 8385381
[TBL] [Abstract][Full Text] [Related]
18. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
19. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.
Webb SM; Rigla M; Wägner A; Oliver B; Bartumeus F
J Clin Endocrinol Metab; 1999 Oct; 84(10):3696-700. PubMed ID: 10523016
[TBL] [Abstract][Full Text] [Related]
20. Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.
Losa M; Spatola G; Albano L; Gandolfi A; Del Vecchio A; Bolognesi A; Mortini P
Endocrine; 2017 Jun; 56(3):595-602. PubMed ID: 27688011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
